drugset / Trial / NCT05457894

Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

NCT05457894

RandomizedParallel-groupDouble-blindPrevention

Summary

Comparative study of tolerability, reactogenicity, safety and immunogenicity Flu-M \[Inactivated Split Influenza Vaccine\] vs. the Ultrix® vaccine for the prevention of influenza in pregnant women in the 2nd-3rd trimesters of pregnancy

Timeline

Start
2020-01-23
Primary completion
2021-03-11
Completion
2021-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Flu-M Vaccine 0.5 ml Intramuscular
Comparator Ultrix Vaccine 0.5 ml Intramuscular

Indications